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Abstract 
Introduction 
Cystic fibrosis characterized by abnormal transport of sodium and 
chloride across an epithelium by defective genes, resulting in thick 
mucus secretions.  
 Enhancement of therapy practices to advance outcomes is an area of 
cystic fibrosis care, which has progressed significantly over the last 
few decades.  As the choices of treatment for CF increases, the 
clinicians are confronted with the predicament of developing a 
treatment plan that provides optimal benefit, addresses the complex 
therapeutic routine on patient compliance and is cost effective. 
 Today, CF patients are living longer and clinicians need to recognize 
and implement early treatment to maintain optimal outcome. An 
early efficient management of children with CF is a road map to 
increasing the quality of life and health status of these patients as 
they transition to adulthood. 
Research Question 
Literature Review 




 In a controlled long-term trial, treatment with hypertonic saline 
for one year had an adequate yet continued improvement in the 
level of lung function. 
More interesting, however, were the apparent reduction rates of 
exacerbations, antibiotic use, and overall improvement of 
quality of life that were associated with use of hypertonic 
saline. 
 Eng et al. (1996) observed improvement of 15% in FEV1 from 
baseline with 6% hypertonic saline compared to isotonic saline..  
Hypertonic saline treatment is inexpensive and safe as an 
additional therapy in patients with cystic fibrosis and can play 




Cystic fibrosis is an autosomal recessive genetic disorder that 
severely affects the lungs as well as other organs in the body. The 
pathophysiology of cystic fibrosis lung disease involves the 
production of thick and sticky mucus that accumulates leading to 
obstruction and inflammation of the airways. This disease is 
characterized by abnormal transport of sodium and chloride across 
an epithelium by defective genes, resulting in thick mucus 
secretions. 
Nebulized hypertonic saline (3% NaCl) improves mucociliary 
clearance through rehydration of the airway surface liquid of the 
lungs. The purpose of this study is to evaluate the effects of 
nebulized hypertonic saline in improving lung function and 
decreasing exacerbation rates in older children (10-18 years of 
age) and adults with stable cystic fibrosis compared to normal 
saline (0.9%). 
The review of literature will focus on comparing the use of 
nebulized hypertonic saline in enhancing mucociliary clearance in 
CF patients compared to other methods. The expected outcome is 
that nebulized hypertonic saline treatment will improve lung 
function and decrease exacerbation of CF in these groups. 
In older children and adults with stable cystic fibrosis who have 
failed to show improvement with recombinant human 
deoxyribonuclease (rhDNase) does treatment with nebulized 
hypertonic saline improve lung function, forced expiatory 
volume in one second (FEV1) and pulmonary exacerbation 
compared to NS?  
 
Gupta et al. (2012) conducted a randomized control trial in 
which 31 children diagnosed with cystic fibrosis were 
administered either 3% saline or 7% saline for 28 days.   
  Peak expiratory flow rate improved from 172.7 l/min at a 
baseline to 195.3 l/min on day 28 of the trial in the group 
that received the 3% hypertonic saline and from 194l/min 
to 212 l/min in the group that received the 7% saline.  
Eng et  al. (1996) conducted a 48 week double-blind study in 
which patients were  randomly assigned to inhale 4ml of either 7 
percent hypertonic saline or 0.9 percent saline twice daily for 48 
weeks. 
The group that received the hypertonic saline treatment 
had significantly higher FVC (at 82ml; 95% confidence 
interval, 12, to 153) and  FEV1 (at 68ml; 95% confidence 
interval, 3 to 132) values, but parallel FEF25-75 values. 
Hypertonic saline had significantly greater numbers of 
patients without pulmonary exacerbation (76% compared 
with 62% in the control group;   P=0.03). 
Figure 1 
Nebulized hypertonic saline illustrates tangible improvement in 
mucus clearance without major adverse effects by reducing the 
number of exacerbation, use of antibiotics, and improving lung 
function.  
Hypertonic saline achieves this function by its direct effect on 
mucus, breaking the ionic bonds leading to lower viscosity and 
elasticity. 
Hypertonic saline has been shown to improve mucociliary 
clearance in patients with cystic fibrosis and recent studies 
provide indication for clinical efficacy for hypertonic saline in 
cystic fibrosis.  
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Statement of the Problem 
With the practices of newborn screening and an increase in life 
expectancy, the management of individuals with CF must adapt to a 
more vigorous and individualized methodology and CF 
physiotherapy management needs to reflect the shifting landscape, 
with increasing life expectancy and decreasing disease burden in CF 
patients. 
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The CFTR protein is a channel protein that controls the flow of H2O and Cl- 
ions. When the CFTR protein is working correctly (Panel 1) ions freely flow in 
and out of the cells. However, when the CFTR protein is malfunctioning (Panel 
2) Ions cannot flow out of the cell due to a blocked channel (Karl 
Kunzelmanet, 2000). 
Absolute Change from Baseline in Forced Vital Capacity (FVC) 
(Panel A) and the Forced Expiratory Volume in One Second (FEV1) 
(Panel B) (Elkins, 2006). 
